

# Dennis Paul

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9507252/publications.pdf>

Version: 2024-02-01

58  
papers

1,507  
citations

394421

19  
h-index

302126

39  
g-index

60  
all docs

60  
docs citations

60  
times ranked

1509  
citing authors

#	ARTICLE	IF	CITATIONS
1	Gender effects and central opioid analgesia. <i>Pain</i> , 1991, 45, 87-94.	4.2	167
2	A possible role for nerve growth factor in the augmentation of sodium channels in models of chronic pain. <i>Brain Research</i> , 2000, 854, 19-29.	2.2	145
3	Different $\mu$ receptor subtypes mediate spinal and supraspinal analgesia in mice. <i>European Journal of Pharmacology</i> , 1989, 168, 307-314.	3.5	125
4	Ibuprofen blocks changes in $\nu$ 1.7 and 1.8 sodium channels associated with complete Freund's adjuvant-induced inflammation in rat. <i>Journal of Pain</i> , 2004, 5, 270-280.	1.4	116
5	Differential development of acute tolerance to analgesia, respiratory depression, gastrointestinal transit and hormone release in a morphine infusion model. <i>Life Sciences</i> , 1989, 45, 1627-1636.	4.3	114
6	PDZK1 Is a Novel Factor in Breast Cancer That Is Indirectly Regulated by Estrogen through IGF-1R and Promotes Estrogen-Mediated Growth. <i>Molecular Medicine</i> , 2013, 19, 253-262.	4.4	90
7	Genetic influences in opioid analgesic sensitivity in mice. <i>Brain Research</i> , 1991, 566, 295-298.	2.2	77
8	Potentiation of opioid analgesia by the antidepressant nefazodone. <i>European Journal of Pharmacology</i> , 1992, 211, 375-381.	3.5	64
9	Differential blockade by naloxazine of two $\mu$ opiate actions: Analgesia and inhibition of gastrointestinal transit. <i>European Journal of Pharmacology</i> , 1988, 149, 403-404.	3.5	54
10	Comparison of naloxazine and $\delta$ -funaltrexamine antagonism of $\mu$ 1 and $\mu$ 2 opioid actions. <i>Life Sciences</i> , 1991, 48, 2005-2011.	4.3	52
11	Blockade of morphine analgesia by both pertussis and cholera toxins in the periaqueductal gray and locus coeruleus. <i>Brain Research</i> , 1990, 529, 324-328.	2.2	33
12	Oxidation-sensitive nociception involved in endometriosis-associated pain. <i>Pain</i> , 2015, 156, 528-539.	4.2	32
13	Synergistic analgesic interactions between the periaqueductal gray and the locus coeruleus. <i>Brain Research</i> , 1991, 558, 224-230.	2.2	31
14	Ranolazine attenuates behavioral signs of neuropathic pain. <i>Behavioural Pharmacology</i> , 2009, 20, 755-758.	1.7	31
15	Synthesis and in vivo evaluation of non-hepatotoxic acetaminophen analogs. <i>Bioorganic and Medicinal Chemistry</i> , 2007, 15, 2206-2215.	3.0	30
16	Selective effects of pirenperone on analgesia produced by morphine or electrical stimulation at sites in the nucleus raphe magnus and periaqueductal gray. <i>Psychopharmacology</i> , 1986, 88, 172-176.	3.1	27
17	Chronic opioid antagonist treatment increases $\mu$ and $\delta$ receptor mediated spinal cord opioid analgesia. <i>Brain Research</i> , 1989, 485, 176-178.	2.2	25
18	Attenuation of morphine analgesia by the $\delta$ 2 antagonists, pirenperone and ketanserin. <i>Pharmacology Biochemistry and Behavior</i> , 1988, 31, 641-647.	2.9	24

#	ARTICLE	IF	CITATIONS
19	Reduction in opioid and non-opioid forms of swim analgesia by 5-HT <sub>2</sub> receptor antagonists. <i>Brain Research</i> , 1989, 500, 231-240.	2.2	22
20	Synthesis and Biological Evaluation at Nicotinic Acetylcholine Receptors of N-Arylalkyl- and N-Aryl-7-Azabicyclo[2.2.1]heptanes. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 3041-3047.	6.4	19
21	Analgesic effects of Tyr-W-MIF-1: a mixed $\mu$ <sub>2</sub> -opioid receptor antagonist. <i>European Journal of Pharmacology</i> , 1996, 316, 33-38.	3.5	18
22	Differential cross-tolerance between analgesia produced by $\mu$ <sub>2</sub> -adrenoceptor agonists and receptor subtype selective opioid treatments. <i>European Journal of Pharmacology</i> , 1995, 272, 111-114.	3.5	17
23	Intrathecal Tyr-W-MIF-1 produces potent, naloxone-reversible analgesia modulated by $\mu$ <sub>2</sub> -adrenoceptors. <i>European Journal of Pharmacology</i> , 1996, 298, 235-239.	3.5	17
24	Ranolazine Attenuation of CFA-induced Mechanical Hyperalgesia. <i>Pain Medicine</i> , 2010, 11, 119-126.	1.9	15
25	Ranolazine Attenuates Mechanical Allodynia Associated with Demyelination Injury. <i>Pain Medicine</i> , 2014, 15, 1771-1780.	1.9	15
26	Regulation and pharmacological blockade of sodium-potassium ATPase: A novel pathway to neuropathy. <i>Journal of the Neurological Sciences</i> , 2014, 340, 139-143.	0.6	15
27	Selective lysis of breast carcinomas by simultaneous stimulation of sodium channels and blockade of sodium pumps. <i>Oncotarget</i> , 2018, 9, 15606-15615.	1.8	15
28	Cross-tolerance between analgesia produced by xylazine and selective opioid receptor subtype treatments. <i>European Journal of Pharmacology</i> , 2000, 389, 181-185.	3.5	13
29	Medications of abuse in pain management. <i>Current Opinion in Anaesthesiology</i> , 2007, 20, 319-324.	2.0	12
30	Measurement of CFA-Induced Hyperalgesia and Morphine-Induced Analgesia in Rats: Dorsal vs Plantar Mechanical Stimulation of the Hindpaw. <i>Pain Medicine</i> , 2011, 12, 451-458.	1.9	12
31	Hydrocodone extended-release: Pharmacodynamics, pharmacokinetics and behavioral pharmacology of a controversy. <i>Pharmacological Research</i> , 2015, 91, 99-103.	7.1	12
32	The effects of postmortem delay on mu, delta and kappa opioid receptor subtypes in rat brain and guinea pig cerebellum evaluated by radioligand receptor binding. <i>Life Sciences</i> , 1997, 61, 1993-1998.	4.3	11
33	Effects of $\mu$ <sub>2</sub> -opioid receptor agonists on stimulated phosphoinositide hydrolysis in rat kidney. <i>European Journal of Pharmacology</i> , 1995, 289, 411-417.	2.6	8
34	Analgesic potency of TRIMU-5: A mixed $\mu$ <sub>2</sub> opioid receptor agonists/ $\mu$ <sub>1</sub> opioid receptor antagonist. <i>European Journal of Pharmacology</i> , 1992, 216, 249-255.	3.5	7
35	Evidence of hyperglycemic hyperalgesia by quinpirole. <i>Pharmacology Biochemistry and Behavior</i> , 1992, 41, 65-67.	2.9	7
36	Insulin Is Essential for the Recovery from Allodynia Induced by Complete Freund's Adjuvant. <i>Pain Medicine</i> , 2010, 11, 1401-1410.	1.9	6

#	ARTICLE	IF	CITATIONS
37	Targeted Osmotic Lysis of Highly Invasive Breast Carcinomas Using Pulsed Magnetic Field Stimulation of Voltage-Gated Sodium Channels and Pharmacological Blockade of Sodium Pumps. <i>Cancers</i> , 2020, 12, 1420.	3.7	5
38	A novel pipeline of 2-(benzenesulfonamide)-N-(4-hydroxyphenyl) acetamide analgesics that lack hepatotoxicity and retain antipyresis. <i>European Journal of Medicinal Chemistry</i> , 2020, 202, 112600.	5.5	4
39	Pirenperone does not attenuate morphine analgesia in spinal rats. <i>Psychopharmacology</i> , 1990, 100, 98-101.	3.1	3
40	Potential of intrathecal DAMGO antinociception, but not gastrointestinal transit inhibition, by 5-hydroxytryptamine and norepinephrine uptake blockade. <i>Life Sciences</i> , 1994, 56, PL83-PL87.	4.3	3
41	Emergency Use of Targeted Osmotic Lysis for the Treatment of a Patient with Aggressive Late-Stage Squamous Cell Carcinoma of the Cervix. <i>Current Oncology</i> , 2021, 28, 2115-2122.	2.2	3
42	Targeted Osmotic Lysis: A Novel Approach to Targeted Cancer Therapies. <i>Biomedicines</i> , 2022, 10, 838.	3.2	3
43	Associative factors in tolerance to analgesia produced by electrical stimulation in the brainstem. <i>Behavioral Neuroscience</i> , 1990, 104, 207-216.	1.2	2
44	Critical appraisal of extended-release hydrocodone for chronic pain: patient considerations. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 1635.	2.0	2
45	Drug-Receptor Interactions. , 2007, , 1-3.		1
46	Targeted Osmotic Lysis Emergency Use Treatment of a Patient with Aggressive, Late-Stage Cervical Cancer. <i>FASEB Journal</i> , 2021, 35, .	0.5	1
47	Opioids and the Control of Pain. , 1996, , 167-192.		1
48	Quantitative Parameters of Drug Action. , 2007, , 1-6.		0
49	Classical Models for Drug Receptor Interactions. , 2007, , 1-4.		0
50	Relative Expression of Voltage-Gated Sodium Channels in Cancerous and Noncancerous Cells during the Cell Cycle. <i>FASEB Journal</i> , 2021, 35, .	0.5	0
51	Potential of Delta Opioid Receptor Inhibition of Adenyl Cyclase Activity By 5-HT <sub>3</sub> Receptor Stimulation in Intact NG108-15 Cells. <i>FASEB Journal</i> , 2011, 25, .	0.5	0
52	A Curriculum for Teaching Scientific Presentation Skills to Graduate Students. <i>FASEB Journal</i> , 2012, 26, 719.12.	0.5	0
53	Targeted Osmotic Lysis of Highly Invasive Carcinomas Using a Pulsed Magnetic Field and Pharmacological Blockade of Voltage-Gated Sodium Channels. <i>FASEB Journal</i> , 2018, 32, 565.3.	0.5	0
54	Targeted Osmotic Lysis of H28 Mesothelioma Cells. <i>FASEB Journal</i> , 2019, 33, 675.9.	0.5	0

#	ARTICLE	IF	CITATIONS
55	A Comprehensive Proteomic Analysis of Metastatic Cancer Progression in a Murine Model of Tumorigenesis Using Orbitrap Tandem Mass Spectrometry. FASEB Journal, 2019, 33, 509.7.	0.5	0
56	A Standardized, Scalable Method to Quantify in Vitro Invasiveness. FASEB Journal, 2022, 36, .	0.5	0
57	Targeted Osmotic Lysis of Advanced Carcinoma in Companion Animals. FASEB Journal, 2022, 36, .	0.5	0
58	Dividing Cells are Most Susceptible to Targeted Osmotic Lysis Cancer Therapy. FASEB Journal, 2022, 36, .	0.5	0